SG11201810853UA - Anti-tnfrsf25 antibodies - Google Patents

Anti-tnfrsf25 antibodies

Info

Publication number
SG11201810853UA
SG11201810853UA SG11201810853UA SG11201810853UA SG11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA SG 11201810853U A SG11201810853U A SG 11201810853UA
Authority
SG
Singapore
Prior art keywords
international
antibodies
pct
durham
english
Prior art date
Application number
SG11201810853UA
Inventor
Taylor H Schreiber
Jeff T Hutchins
Original Assignee
Pelican Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pelican Therapeutics Inc filed Critical Pelican Therapeutics Inc
Publication of SG11201810853UA publication Critical patent/SG11201810853UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

WO 17 / 2145 47 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT omit VIII two Hol olommoomommom oimIE (10) International Publication Number WO 2017/214547 Al (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2017/036817 (22) International Filing Date: 09 June 2017 (09.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/348,009 09 June 2016 (09.06.2016) US (71) Applicant: PELICAN THERAPEUTICS, INC. [US/US]; 801 Capitola Drive, Bay 12, Durham, North Car- olina 27713 (US). (72) Inventors: SCHREIBER, Taylor H.; 3611 Rugby Rd, Durham, North Carolina 27707 (US). HUTCHINS, Jeff T.; 15823 S. 4210 Rd., Claremore, Oklahoma 74017 (US). (74) Agent: ALTIERI, Stephen, L.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-TNFRSF25 ANTIBODIES (57) : Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
SG11201810853UA 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies SG11201810853UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662348009P 2016-06-09 2016-06-09
PCT/US2017/036817 WO2017214547A1 (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Publications (1)

Publication Number Publication Date
SG11201810853UA true SG11201810853UA (en) 2019-01-30

Family

ID=59078259

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810853UA SG11201810853UA (en) 2016-06-09 2017-06-09 Anti-tnfrsf25 antibodies

Country Status (15)

Country Link
US (3) US10005843B2 (en)
EP (1) EP3468998B1 (en)
JP (1) JP6961625B2 (en)
KR (1) KR102423942B1 (en)
CN (1) CN109219620B (en)
AU (1) AU2017278192A1 (en)
BR (1) BR112018075222A2 (en)
CA (1) CA3026652A1 (en)
DK (1) DK3468998T3 (en)
IL (1) IL263406B2 (en)
MX (1) MX2018014716A (en)
RU (1) RU2746314C2 (en)
SG (1) SG11201810853UA (en)
WO (1) WO2017214547A1 (en)
ZA (1) ZA201808317B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3253876T3 (en) * 2015-02-06 2021-01-25 Heat Biologics Inc VECTOR CO-EXPRESSING VACCINE AND COSTIMULATING MOLECULES
WO2022212668A1 (en) * 2021-03-31 2022-10-06 Heat Biologics, Inc. Methods and compositions related to tnfrsf25/dr3 agonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CZ282603B6 (en) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
DE69321218T2 (en) 1992-02-19 1999-02-18 Schering Corp CLONING AND EXPRESSION OF HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
WO2005018571A2 (en) 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
JP5164167B2 (en) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ Agonists, antagonists and immunotoxins of immunoregulatory tumor necrosis factor receptor 25 (TNFR25)
CN103897058B (en) 2006-10-02 2018-06-15 E.R.施贵宝&圣斯有限责任公司 Human antibodies with reference to CXCR4 and application thereof
FR2907341B1 (en) 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
EP2462165B1 (en) 2009-08-03 2016-05-11 University of Miami Method for in vivo expansion of t regulatory cells
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
JP2013040160A (en) 2011-07-01 2013-02-28 Genentech Inc Use of anti-cd83 agonist antibody for treating autoimmune disease
AU2014205366B2 (en) 2013-01-09 2018-12-20 Eckhard R. Podack Compositions and methods for the regulation of T regulatory cells using Tl1a-Ig fusion protein
RU2551235C2 (en) * 2013-08-26 2015-05-20 Илья Владимирович Духовлинов Humanised monoclonal antibody specific to syndecan-1
CN103592439B (en) * 2013-09-03 2015-10-21 天津亿美诺生物科技有限公司 Human urothelial carcinoma specific antibody and application thereof
WO2016081455A1 (en) * 2014-11-17 2016-05-26 Pelican Therapeutics, Inc. Human tnfrsf25 antibody

Also Published As

Publication number Publication date
IL263406B1 (en) 2023-05-01
US20170355773A1 (en) 2017-12-14
ZA201808317B (en) 2019-08-28
CA3026652A1 (en) 2017-12-14
US20180312599A1 (en) 2018-11-01
CN109219620A (en) 2019-01-15
US20210017287A1 (en) 2021-01-21
MX2018014716A (en) 2019-03-11
IL263406B2 (en) 2023-09-01
AU2017278192A1 (en) 2018-12-13
IL263406A (en) 2018-12-31
DK3468998T3 (en) 2022-03-07
US10683359B2 (en) 2020-06-16
JP2019526528A (en) 2019-09-19
RU2746314C2 (en) 2021-04-12
BR112018075222A2 (en) 2019-03-19
EP3468998A1 (en) 2019-04-17
EP3468998B1 (en) 2021-12-01
CN109219620B (en) 2023-01-31
JP6961625B2 (en) 2021-11-10
KR20190015716A (en) 2019-02-14
WO2017214547A1 (en) 2017-12-14
RU2018143977A (en) 2020-07-09
RU2018143977A3 (en) 2020-10-05
KR102423942B1 (en) 2022-07-22
US10005843B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201808196UA (en) Neoantigens and methods of their use
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408261UA (en) Syringe
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201803642WA (en) Bacteria-based protein delivery
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof